Ligand Pharma (LGND) Tops Q2 EPS by 60c
Tweet
Share
E-mailGet Alerts LGND Hot Sheet
Price: $285.60 -1.43%
EPS Growth %: -24.9%
Financial Fact:
Material sales: 4.22M
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: -24.9%
Financial Fact:
Material sales: 4.22M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Ligand Pharma (NASDAQ: LGND) reported Q2 EPS of $1.03, $0.60 better than the analyst estimate of $0.43. Revenue for the quarter came in at $57.4 million versus the consensus estimate of $37.73 million.
For earnings history and earnings-related data on Ligand Pharma (LGND) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU proposes to curb Airbnb and short-term rentals amid housing shortage
- JPMorgan Upgrades Whitehaven Coal Ltd. (WHC:AU) (WHITF) to Overweight
- Goldman Sachs Downgrades Schindler Holding AG (SCHN:SW) (SHLAF) to Sell
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
